Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology
|
Buy Now
Hematopoietic Growth Factors in Oncology (Hardcover, 2011 Ed.)
Loot Price: R5,503
Discovery Miles 55 030
|
|
Hematopoietic Growth Factors in Oncology (Hardcover, 2011 Ed.)
Series: Cancer Treatment and Research, 157
Expected to ship within 10 - 15 working days
|
Progress in the treatment of cancer over the past two decades has
been rapid with many new and novel therapeutic modalities arriving
at an unprecedented pace. Overall cancer mortality rates have
actually begun to fall in parallel with progress in the diagnosis
and treatment of malignant disease. Despite our advances in the
understanding of the biology and molecular genetics of cancer, as
well as the availability of an increasing array of effective
therapies, cancer treatment today and for the foreseeable future
will include the traditional modalities of surgery, radiation
therapy and chemotherapy. Myelosuppressive agents with their
potential hematopoietic toxicities remain the mainstay of systemic
treatment for both metastatic and early stage cancer. The
complications of cancer chemotherapy have serious impact on a
patient's well being and overall quality of life. Fortunately,
advances in cancer treatment have been accompanied by equally
impressive progress in the availability of a wide array of
supportive care modalities which have greatly enhanced the ability
of oncologists to minimize the impact of cancer and its treatment
on patient quality of life as well improve delivery of potentially
curative cancer treatment. Despite the increasing complexity of
modern cancer treatment, it is the obligation of the oncologist as
well as the entire cancer care team to be certain that cancer
patients receive the optimal supportive care available for their
disease and its treatment. Among the most serious and potentially
life threatening toxicities of cancer treatment are the hematologic
toxicities accompanying myelosuppression including anemia and
associated asthenia and fatigue, neutropenia and fever associated
with infection in the immunocompromised patient and
thrombocytopenia and accompanying risk of bleeding. Special
supportive care needs arise in the very elderly care patient that
may tax the ability of even the most skilled clinician. Despite the
considerable progress that has been made with more effective and
safer treatment strategies, myelosuppressive chemotherapy will
remain the mainstay of systemic treatment for cancer for the
foreseeable future. While considerable progress has occurred,
better methods and broader application of supportive care measures
are needed to reduce the symptomatic effects of cancer and the
associated toxicities associated with cancer treatment. No area of
cancer supportive care better illustrates the progress that has
resulted from advances in our understanding of cellular and
molecular biology, genetic engineering and the development of more
effective yet often more toxic cancer treatments than that of the
hematopoietic growth factors. This volume will review and integrate
the major advances in our understanding of the underlying molecular
biology and pharmacology of these agents along with the results of
well designed and executed randomized controlled trials of the
erythroid stimulating agents, the myeloid growth factors and the
new thrombopoietic agents each addressing a major threat associated
with bone marrow suppression accompanying cancer treatment. The
current clinical utilization of these agents is based on numerous
randomized controlled trials and meta-analyses along with
evidence-based clinical practice guidelines developed by
professional societies guiding their appropriate and cost-effective
use in clinical care.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.